Skip to main content

Table 3 Difference in clinicopathological features due to age

From: Differences in tumor-infiltrating lymphocyte density and prognostic factors for breast cancer by patient age

Parameters All intrinsic subtype (n = 191) HR+HER2-BC (n =61) HR+HER2+BC (n =27) HER2BC (n =48) TNBC (n =53)
Young (n =75) Elderly (n = 116) p value Young (n =24) Elderly (n = 39) p value Young (n =16) Elderly (n = 11) p value Young (n =12) Elderly (n = 36) p value Young (n =23) Elderly (n = 30) p value
Tumor size (mm)
 ≤ 20.0 10 (13.3%) 24 (20.7%) 0.194 2 (8.3%) 7 (17.9%) 0.290 3 (18.8%) 2 (18.2%) 0.970 2 (16.7%) 7 (19.4%) 0.831 3 (13.0%) 8 (26.7%) 0.225
 > 20.0 65 (86.7%) 92 (79.3%) 22 (91.7%) 32 (82.1%) 13 (81.2%) 9 (81.8%) 10 (83.3%) 29 (80.6%) 20 (87.0%) 22 (73.3%)
Skin infiltration
 Negative 68 (90.7%) 90 (77.6%) 0.020 20 (83.3%) 29 (74.4%) 0.405 14 (87.5%) 6 (54.5%) 0.055 12 (100.0%) 29 (80.6%) 0.098 22 (95.7%) 26 (86.7%) 0.267
 Positive 7 (9.3%) 26 (22.4%) 4 (16.7%) 10 (25.6%) 2 (12.5%) 5 (45.5%) 0 (0.0%) 7 (19.4%) 1 (4.3%) 4 (13.3%)
Lymph node status
 Negative 28 (37.3%) 44 (37.9%) 0.934 8 (33.3%) 12 (30.8%) 0.832 9 (56.2%) 2 (18.2%) 0.048 4 (33.3%) 17 (47.2%) 0.401 7 (30.4%) 13 (43.3%) 0.337
 Positive 47 (62.7%) 72 (62.1%) 16 (66.7%) 27 (69.2%) 7 (43.8%) 9 (81.8%) 8 (66.7%) 19 (52.8/%) 16 (69.6%) 17 (56.7%)
Estrogen receptor
 Negative 37 (49.3%) 67 (57.8%) 0.254 2 (8.3%) 0 (0.0%) 0.067 0 (0.0%) 1 (9.1%) 0.219   
 Positive 38 (50.7%) 49 (42.2%) 22 (91.7%) 39 (100.0%) 16 (100.0%) 10 (90.9%)
Progesterone receptor
 Negative 42 (56.0%) 89 (76.7%) 0.003 5 (20.8%) 16 (41.0%) 0.099 2 (12.5%) 7 (63.6%) 0.006   
 Positive 33 (44.0%) 27 (23.3%) 19 (79.2%) 23 (59.0%) 14 (87.5%) 4 (36.4%)  
Hormone receptor-
 Negative 35 (46.7%) 66 (56.9%) 0.167     
 Positive 40 (53.3%) 50 (43.1%)
HER2
 Negative 47 (62.7%) 69 (59.5%) 0.660     
 Positive 28 (37.3%) 47 (40.5%)
Ki67
 ≤ 14% 22 (29.3%) 40 (34.5%) 0.458 12 (50.0%) 21 (53.8%) 0.767 7 (43.8%) 2 (18.2%) 0.166 1 (8.3%) 12 (33.3%) 0.091 2 (8.7%) 5 (16.7%) 0.396
 > 14% 53 (70.7%) 76 (65.5%) 12 (50.0%) 18 (46.2%) 9 (56.2%) 9 (81.8%) 11 (91.7%) 24 (66.7%) 21 (91.3%) 25 (83.3%)
ORR
 Non-responders 5 (6.7%) 17 (14.8%) 0.091 2 (8.3%) 8 (20.5%) 0.199 0 (0.0%) 4 (36.4%) 0.009 0 (0.0%) 1 (2.8%) 0.560 3 (13.0%) 4 (13.3%) 0.975
 Responders 70 (93.3%) 99 (85.2%) 22 (91.7%) 31 (79.5%) 16 (100.0%) 7 (63.6%) 12 (100.0%) 35 (97.2%) 20 (87.0%) 26 (86.7%)
Pathological response
 Non-pCR 46 (61.3%) 78 (67.2%) 0.403 18 (75.0%) 37 (94.9%) 0.021 13 (81.2%) 10 (90.9%) 0.488 1 (8.3%) 14 (38.9%) 0.048 14 (60.9%) 17 (56.7%) 0.758
 pCR 29 (38.7%) 38 (32.8%) 6 (25.0%) 2 (5.1%) 3 (18.8%) 1 (9.1%) 11 (91.7%) 22 (61.1%) 9 (39.1%) 13 (43.3%)
TILs
 Low 31 (41.3%) 65 (56.0%) 0.047 14 (58.3%) 31 (79.5%) 0.071 7 (43.8%) 9 (81.8%) 0.048 1 (8.3%) 10 (27.8%) 0.165 9 (39.1%) 15 (50.0%) 0.431
 High 44 (58.7%) 51 (44.0%) 10 (41.7%) 8 (20.5%) 9 (56.2%) 2 (18.2%) 11 (91.7%) 26 (72.2%) 14 (60.9%) 15 (50.0%)
  1. HER human epidermal growth factor receptor, ORR objective response rate, CR complete response, TILs tumor-infiltrating lymphocytes